Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

TRK Inhibition: A New Tumor-Agnostic Treatment Strategy
Shivaani Kummar, Ulrik Lassen
Targeted Oncology (2018) Vol. 13, Iss. 5, pp. 545-556
Open Access | Times Cited: 89

Showing 1-25 of 89 citing articles:

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong, Steven G. DuBois, Shivaani Kummar, et al.
The Lancet Oncology (2020) Vol. 21, Iss. 4, pp. 531-540
Open Access | Times Cited: 847
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
Alessio Amatu, Andrea Sartore‐Bianchi, Katia Bencardino, et al.
Annals of Oncology (2019) Vol. 30, pp. viii5-viii15
Open Access | Times Cited: 234
Larotrectinib: First Global Approval
Lesley J. Scott
Drugs (2019) Vol. 79, Iss. 2, pp. 201-206
Closed Access | Times Cited: 205
Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy
Susan J. Hsiao, Ahmet Zehir, Anthony Sireci, et al.
Journal of Molecular Diagnostics (2019) Vol. 21, Iss. 4, pp. 553-571
Open Access | Times Cited: 195
Testing algorithm for identification of patients with TRK fusion cancer
Frédérique Penault‐Llorca, Erin R. Rudzinski, Antonia R. Sepulveda
Journal of Clinical Pathology (2019) Vol. 72, Iss. 7, pp. 460-467
Open Access | Times Cited: 160
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
François Doz, Cornelis M. van Tilburg, Birgit Geoerger, et al.
Neuro-Oncology (2021) Vol. 24, Iss. 6, pp. 997-1007
Open Access | Times Cited: 127
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network
George D. Demetri, Cristina R. Antonescu, Bodil Bjerkehagen, et al.
Annals of Oncology (2020) Vol. 31, Iss. 11, pp. 1506-1517
Open Access | Times Cited: 124
NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target
Alessandro Gambella, Rebecca Senetta, Giammarco Collemi, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 3, pp. 753-753
Open Access | Times Cited: 95
Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion
Eileen M. O’Reilly, Jaclyn F. Hechtman
Annals of Oncology (2019) Vol. 30, pp. viii36-viii40
Open Access | Times Cited: 90
NTRK Fusion Genes in Thyroid Carcinomas: Clinicopathological Characteristics and Their Impacts on Prognosis
Barbora Pekova, Vlasta Sýkorová, Karolina Mastnikova, et al.
Cancers (2021) Vol. 13, Iss. 8, pp. 1932-1932
Open Access | Times Cited: 80
Expanding the Molecular Spectrum of Secretory Carcinoma of Salivary Glands With a Novel VIM-RET Fusion
Alena Skálová, Martina Baněčková, Lester D.�R. Thompson, et al.
The American Journal of Surgical Pathology (2020) Vol. 44, Iss. 10, pp. 1295-1307
Closed Access | Times Cited: 78
Harnessing the predictive power of preclinical models for oncology drug development
Alexander Honkala, Sanjay V. Malhotra, Shivaani Kummar, et al.
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 2, pp. 99-114
Closed Access | Times Cited: 67
High-grade Transformation/Dedifferentiation in Salivary Gland Carcinomas: Occurrence Across Subtypes and Clinical Significance
Alena Skálová, Ilmo Leivo, Henrik Hellquist, et al.
Advances in Anatomic Pathology (2021) Vol. 28, Iss. 3, pp. 107-118
Open Access | Times Cited: 65
Novel therapeutic strategies for rare mutations in non-small cell lung cancer
Qitao Gou, Qiheng Gou, Xiaochuan Gan, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 13
Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer
Noah Federman, Ray McDermott
Expert Review of Clinical Pharmacology (2019) Vol. 12, Iss. 10, pp. 931-939
Open Access | Times Cited: 62
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer
Sara Elena Rebuzzi, Lodovica Zullo, Giovanni Rossi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2625-2625
Open Access | Times Cited: 52
NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects
Vasiliki Siozopoulou, Evelien Smits, Koen De Winne, et al.
Diagnostics (2021) Vol. 11, Iss. 3, pp. 478-478
Open Access | Times Cited: 45
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers
Xiuning Le, Christina Baik, Jessica R. Bauman, et al.
The Oncologist (2022) Vol. 29, Iss. 6, pp. e779-e788
Open Access | Times Cited: 30
Salivary Gland Secretory Carcinoma
Martina Baněčková, Lester D.�R. Thompson, Martin Hyrcza, et al.
The American Journal of Surgical Pathology (2023) Vol. 47, Iss. 6, pp. 661-677
Closed Access | Times Cited: 17
Testing NTRK testing: Wet‐lab and in silico comparison of RNA‐based targeted sequencing assays
Nicole Pfarr, Martina Kirchner, Ulrich Lehmann, et al.
Genes Chromosomes and Cancer (2019) Vol. 59, Iss. 3, pp. 178-188
Closed Access | Times Cited: 54
Detecting disease‐defining gene fusions in unclassified round cell sarcomas using anchored multiplex PCR/targeted RNA next‐generation sequencing—Molecular and clinicopathological characterization of 16 cases
José G. Mantilla, Robert W. Ricciotti, Eleanor Y. Chen, et al.
Genes Chromosomes and Cancer (2019) Vol. 58, Iss. 10, pp. 713-722
Closed Access | Times Cited: 40
Methods for Identifying Patients with Tropomyosin Receptor Kinase (TRK) Fusion Cancer
Derek Wong, Stephen Yip, Poul H. Sorensen
Pathology & Oncology Research (2019) Vol. 26, Iss. 3, pp. 1385-1399
Open Access | Times Cited: 40
Pan-TRK Immunohistochemistry: An Example-Based Practical Approach to Efficiently Identify Patients With NTRK Fusion Cancer
Esther Conde, Susana Hernández, Elena Eyre, et al.
Archives of Pathology & Laboratory Medicine (2020) Vol. 145, Iss. 8, pp. 1031-1040
Open Access | Times Cited: 37
Comparative epigenetic analysis of tumour initiating cells and syngeneic EPSC-derived neural stem cells in glioblastoma
Claire Vinel, Gabriel Rosser, Loredana Guglielmi, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 28
A Two-Step Diagnostic Approach for NTRK Gene Fusion Detection in Biliary Tract and Pancreatic Adenocarcinomas
Anne Demols, Laureen Rocq, Luis Pérez-Casanova, et al.
The Oncologist (2023) Vol. 28, Iss. 7, pp. e520-e525
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top